The treatment era for multiple sclerosis began in 1993 with the approval of the first disease‐
modifying therapy. This changed the management of multiple sclerosis from treating acute …

The development of disease‐modifying therapies (DMT) in multiple sclerosis (MS) has
rapidly evolved over the last few years and continues to do so. Prior to the United States …

Background The use of interferon beta and glatiramer acetate for the treatment of multiple
sclerosis (MS) has, to some extent, changed the course of the disease. The annual relapse …

Objective: To summarize major clinical trials which evaluate the efficacy and safety data of
approved disease modifying agents for the treatment of various types of multiple sclerosis …

Purpose We compared the effectiveness and safety of disease-modifying drugs for the
treatment of multiple sclerosis: Glatiramer acetate (Copaxone®), interferon beta-1a …

In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of
relapsing-remitting multiple sclerosis (RRMS) has been established. Interferon beta has also …

The treatment of multiple sclerosis (MS) falls into 3 categories: treatment of exacerbations,
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …

Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and
neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of …

Multiple sclerosis (MS) is considered an autoimmune disease associated with immune
activity directed against central nervous system antigens. Based on this concept …

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the
central nervous system. It affects approximately 400,000 people in the United States and …